Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR-hTNF Monotherapy in Advanced Malignant Pleural Mesothelioma
NCT00484276Phase 2Completed
- Sponsor
- AGC Biologics
- Start
- May 2007
- Primary completion
- Mar 2013
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGR-TNF in malignant pleural mesothelioma (MPM), sponsored by AGC Biologics. Primary endpoint: Progression Free Survival. Started May 2007; status: completed.
02
Drugs
NGR-TNF
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00484276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484276.